ACKR3 and neoplasm: Medicine targeting CXCR7 such as small molecules CCX266, CCX662, CCX733, CCX771, and X7Ab, have been developed to inhibit β-arrestin signaling, thereby inhibiting proliferation, growth, and metastasis of tumor cells.